This rate of cardiac toxicity is leaner compared to the 4 % threshold that is generally considered acceptable, and still lower than what was found in larger, previously published trials evaluating conventionally scheduled treatment by using trastuzumab. The study’s authors concluded that this dose-dense regimen combined with trastuzumab is normally a safe and effective way to treat women with early-stage HER2-positive breast cancers in the adjuvant placing and there is no need to forgo the usage of this program because trastuzumab is also being administered. Chau Dang, MD, a medical oncologist on the Breast Tumor Medicine Services at MSKCC, led the study, and Clifford Hudis, MD, Chief of the Breasts Cancer Medicine Services at MSKCC, is the paper’s senior writer. The scholarly study will be released in the March 10, 2008, problem of the Journal of Clinical Oncology and was backed by grants from Genentech and Amgen. Bird flu loss of life toll in Indonesia up to 48 now Based on the Ministry of Wellness in Indonesia a fresh case of the H5N1 avian influenza virus offers been verified in a young young lady.

Cholesterol Tests Results Interpretation of cholesterol and triglyceride levels in the bloodstream are based upon guidelines from a number of medical organizations like the American Heart Association. Total cholesterolLess than 200 mg/dL: desired200-239 mg/dL: borderline high risk240 and over: high risk HDL Less than 40 mg/dL , less than 50 mg/dL : increased risk of center diseaseGreater than 60mg/dL: some safety against cardiovascular disease LDL Significantly less than 100 mg/dL: optimum100-129 mg/dL: near optimal/above ideal130-159 mg/dL: borderline high160 – 189 mg/dL: high190 mg/dL and above: very high Triglycerides Significantly less than n150 mg/dL: regular150-199 mg/dL: borderline to high200-499mg/dL: highAbove 500 mg/dL: high.This rate of cardiac toxicity is leaner compared to the 4 % threshold that is generally considered acceptable, and still lower than what was found in larger, previously published trials evaluating conventionally scheduled treatment by using trastuzumab. The study’s authors concluded that this dose-dense regimen combined with trastuzumab is normally a safe and effective way to treat women with early-stage HER2-positive breast cancers in the adjuvant placing and there is no need to forgo the usage of this program because trastuzumab is also being administered. Chau Dang, MD, a medical oncologist on the Breast Tumor Medicine Services at MSKCC, led the study, and Clifford Hudis, MD, Chief of the Breasts Cancer Medicine Services at MSKCC, is the paper’s senior writer. The scholarly study will be released in the March 10, 2008, problem of the Journal of Clinical Oncology and was backed by grants from Genentech and Amgen.

Bird flu loss of life toll in Indonesia up to 48 now Based on the Ministry of Wellness in Indonesia a fresh case of the H5N1 avian influenza virus offers been verified in a young young lady.

Other entries from category "clinical":

Random entries